Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.33%
1,098.49
-3.69
-0.33%
1,102.181,096.241,103.051,090.35
SIXC
Communications
SIXC
Communications
SIXC
-0.31%
614.32
-1.92
-0.31%
616.24616.24617.68609.10
SIXE
Energy
SIXE
Energy
SIXE
+0.76%
1,198.73
+9.01
+0.76%
1,189.721,194.741,202.791,188.58
SIXI
Industrials
SIXI
Industrials
SIXI
+1.62%
1,753.66
+27.97
+1.62%
1,725.691,730.021,762.991,730.02
SIXM
Financials
SIXM
Financials
SIXM
-0.74%
638.84
-4.78
-0.74%
643.62643.13643.17632.59
SIXR
Staples
SIXR
Staples
SIXR
+1.72%
844.10
+14.31
+1.72%
829.79832.32844.73832.32
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.87%
215.26
+1.86
+0.87%
213.40213.40216.05213.40
SIXT
Technology
SIXT
Technology
SIXT
-1.67%
3,132.66
-53.26
-1.67%
3,185.923,160.893,178.723,102.60
SIXU
Utilities
SIXU
Utilities
SIXU
+2.41%
930.86
+21.92
+2.41%
908.94912.57932.62912.57
SIXV
Health care
SIXV
Health care
SIXV
-0.14%
1,476.83
-2.13
-0.14%
1,478.961,478.171,482.911,466.65
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.05%
2,380.21
-25.15
-1.05%
2,405.362,390.342,402.532,359.18
4536:TYO
Santen Pharmaceutical Co Ltd
¥1,663.00
-1.19%
(-20.00) 1D
Apr 23, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4536...
Open
¥1,666
High
¥1,676
Low
¥1,649
Mkt. cap
535.95B
Avg. vol.
967.67K
Volume
713.50K
Dividend
2.29%
Quarterly dividend
¥9
Ex dividend date
Sep 29, 2025
P/E ratio
18.07
52-wk high
¥1,939
52-wk low
¥1,397
EPS
¥92
Shares outstanding
407.09M
No. of employees
4K
News stories
From sources across the web
Profile
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries. The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established. In 2014 Santen announced that it has entered into an agreement with Merck & Co. to purchase Merck's ophthalmology products. Wikipedia
About Santen Pharmaceutical Co Ltd
CEOAkira Kurokawa | Shigeo Taniuchi
Employees3.85K
Founded1890
HeadquartersOsaka, Kansai, Japan
SectorPharmaceutical industry
Websitesanten.com
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
77.23B
68.74B
69.14B
72.88B
Cost of goods sold
31.34B
31.62B
29.06B
32.14B
Cost of revenue
31.34B
31.62B
29.06B
32.14B
Research and development expenses
7.33B
6.21B
6.16B
6.00B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18.60B
21.20B
21.31B
22.27B
Operating expense
32.80B
29.54B
29.74B
30.45B
Total operating expenses
64.13B
61.16B
58.80B
62.58B
Operating income
13.10B
7.57B
10.34B
10.30B
Other non operating income
15.00M
-1.00M
-
2.00M
EBT including unusual items
12.17B
7.45B
10.18B
10.44B
EBT excluding unusual items
14.51B
7.45B
10.18B
10.44B
Income tax expense
3.67B
1.59B
2.19B
2.30B
Effective tax rate
30.13%
21.30%
21.53%
22.00%
Other operating expenses
-184.00M
-42.00M
-6.00M
-28.00M
Net income
8.79B
5.88B
8.06B
7.88B
Net profit margin
11.38%
8.55%
11.66%
10.81%
Earnings per share
-
-
-
-
Interest and investment income
427.00M
627.00M
257.00M
455.00M
Interest expense
-
-749.00M
-415.00M
-318.00M
Net interest expenses
427.00M
-122.00M
-158.00M
137.00M
Depreciation and amortization charges
6.84B
-
-2.18B
-
EBITDA
17.50B
12.07B
15.03B
14.92B
Gain or loss from assets sale
1.10B
-
-
-
AI content may include mistakes. Learn more

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more